期刊
CURRENT MEDICINAL CHEMISTRY
卷 17, 期 17, 页码 1825-1838出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986710791111206
关键词
Neurodegenerative diseases; multi-target-directed ligands (MTDLs); dual binding acetylcholinesterase inhibitors; tacrine; tacrine homodimers; tacrine heterodimers; tacrine hybrids
资金
- MIUR, Rome (PRIN)
- University of Bologna (RFO)
- Polo Scientifico-Didattico di Rimini
To date, the pharmacotherapy of Alzheimer's disease (AD) has relied on acetylcholinesterase (AChE) inhibitors (AChEIs) and, more recently, an N-methyl-D-aspartate receptor (NMDAR) antagonist. AD is a multifactorial syndrome with several target proteins contributing to its etiology. Multi-target-directed ligands (MTDLs) have great potential for treating complex diseases such as AD because they can interact with multiple targets. The design of compounds that can hit more than one specific AD target thus represents an innovative strategy for AD treatment. Tacrine was the first AChEI introduced in therapy. Recent studies have demonstrated its ability to interact with different AD targets. Furthermore, numerous tacrine homo- and heterodimers have been developed with the aim of improving and enlarging its biological profile beyond its ability to act as an AChEI. Several tacrine hybrid derivatives have been designed and synthesized with the same goal. This review will focus on and summarize the last two years of research into the development of tacrine derivatives able to hit AD targets beyond simple AChE inhibition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据